Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial

Rob, L., Cibula, D., Knapp, P., Mallmann, P., Klat, J., Minar, L., Bartos, P., Chovanec, J., Valha, P., Pluta, M., Novotny, Z., Spacek, J., Melichar, B., Kieszko, D., Fucikova, J., Hrnciarova, T., Korolkiewicz, R. P., Hraska, M., Bartunkova, J. and Spisek, R. Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial. Journal for ImmunoTherapy of Cancer. 2022; 10(1), p. e003190. doi: 10.1136/jitc-2021-003190